Introduction
Acute myeloid leukemia arises from the clonal expansion of a malignant transformed progenitor cell. [1] [2] [3] [4] [5] [6] [7] [8] In 70-80% of the patients with AML complete remission can be achieved by intensive chemotherapy. However 50-70% of adults with AML will ultimately relapse due to persistent leukemia below the level of morphological detectability. 9, 10 Several techniques have been developed to detect minimal residual disease, such as immunophenotyping, molecular biology, conventional cytogenetic analysis and fluorescence in situ hybridization (FISH). [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Freireich et al 18 analyzed 71 patients in complete clinical and hematological remission for the persistence of cytogenetic abnormalities. Twenty patients (28%) revealed a persistence of their leukemia-specific clonal chromosomal abnormality present in the pretreatment marrow. All 20 patients relapsed within 78 weeks. Fifty-one patients showed a normal karyotype. However, 20 of these patients relapsed and only 21 remained in continuous complete remission. Thus there was a 49% false negative rate in this study. Nylund et al 19 used fluorescence in situ hybridization (FISH) to detect minimal residual disease in 25 follow-up samples of patients with AML (11 patients), CML (four), ALL (seven), NHL (two) and MDS (one). Eight of 11 patients with AML had a trisomy 8, three patients revealed a 15;17 translocation. Only one of 11 patients had a trisomy 8 in 16% of 66 analyzed cells and died 22 months after diagnosis. Using RT-PCR a persistence of detectable levels of the AML1-MTG8 transcripts was frequently found in patients with long-term remission of AML with t (8;21) . 20 A qualitative method is therefore not suitable for predicting clinical outcome by RT-PCR monitoring of MRD, however the quantitative RT-PCR method may increase the specificity for the prediction of relapse. 21 In acute promyelocytic leukemia the detection of the PML/RARa fusion gene by RT-PCR correlates with early relapse. 22, 23 Multiparameter flow cytometric analysis permits a sensitive detection of leukemic cells within a heterogeneous bone marrow cell population. In two or three color immunfluorescence analysis the leukemic cells demonstrate multiple differences from their presumed physiological counterparts due to different light scattering properties and an aberrant or asynchronous antigen expression. 24 Using this method it is possible to define an aberrant leukemic immunophenotype in nearly 80% of all cases of AML. The most frequent abnormal immunophenotype found is an asynchronous myeloid antigen expression and the most frequent lymphoid markers coexpressed with myeloid antigens are T cell-associated antigens especially CD7. First studies show a correlation between the amount of aberrant cells and the remission duration. [25] [26] [27] [28] The detection of minimal residual disease may hence be associated with clinical relapse in distinct subtypes of AML and quantification of MRD might be one decisive parameter for the choice of the adequate therapeutic strategy such as the use of unrelated allogenic transplant in patients with high MRD. So far it is not known in which hematopoietic cell compartment these residual leukemic cells reside. Hematopoietic stem cells are characterized by their immunophenotype. They express CD34 and lack CD38. [29] [30] [31] Recent studies showed an involvement of hematopoietic stem cells characterized by a CD34 + /CD38 − immunophenotype in the leukemic process in patients with newly diagnosed acute leukemia. [3] [4] [5] [6] So far there are no data as to whether intensive chemotherapy can eradicate early progenitor cells with leukemia-specific cytogenetic abnormalities. In the following study we examined if cells with an immature stem cell-like immunophenotype and leukemia-specific clonal chromosomal abnormalities can survive intensive chemotherapy in the niche of the stem cell compartment.
Materials and methods

Patients
Bone marrow aspirates of seven patients with AML in morphological complete remission were selected for sorting pro-cedures according to their immunophenotype. Diagnosis and classification of AML were based on light microscopy of Pappenheim-stained slides, and on cytochemical reaction with periodic acid schiff (PAS), myeloperoxidase and esterase. Slides were reviewed by two independent hematologists according to the criteria of the French-American-British (FAB) classification. 32 All patients were treated according to the protocol of the AMLCG 33 depending on their age and remission status after induction therapy with a double induction therapy with TAD (thioguanine, Ara-C, daunorubicin) and HAM (highdose Ara-C and mitoxantrone), a consolidation with TAD followed by a 3-year maintanance therapy with AD (Ara-C and daunorubicin), AT (Ara-C and thioguanine) and AC (Ara-C and cyclophosphamide).
Immunophenotyping
Immunophenotyping was performed at diagnosis by multiparameter flow cytometric analysis with a FACScan (Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA) using a whole blood lysis method ( 
/CD38
− and CD34
+
/CD38
+ population were sorted according to their light scatter properties and fluorescence intensity using a FACS Vantage (Becton Dickinson) equipped with a 488 nm argon laser, Lysis software. The sort purity was Ͼ98%. Appropriate isotype controls were used for setting amplification and compensation of the flow cytometer. The FACS analysis at diagnosis and in morphological complete remission from patient No. 1 with AML M2, add(2) is shown in Figure 1 . 10 000 cells acquired in list mode are shown. The percentage of CD34
− cells during morphological CR was approximately 0.02%, a total of 2230 CD34
− cells could be obtained.
Fluorescence in situ hybridization
For the FISH experiments cells were sorted on to glass microscope slides containing 100 l 0.1% agarose and fixed with methanol:acetic acid, 3:1; vol/vol. Selection of DNA probes was individualized on the basis of the karyotype of each leukemic specimen. Centromeric probes and whole chromosome paint (WCP) probes for chromosome 8 directly labeled with SpectrumOrange were used (Vysis, Naperville, IL, USA). The specimens for whole chromosome painting were preincubated with 0.3 g/ml colcemide (GIBCO) 12 h before the sorting experiments. Cellular DNA was denatured at 74°C for 5 min in 70% formamide, saline sodium citrate (SSC 0.30 mol/l NaCl, 0.03 mol/l sodium citrate, pH 7.0-8.0). After dehydration in ethanol series (70%, 80%, 90%, 100%) and air-drying at 42°C, the DNA probe was denatured in hybridization mixture (formamide 50%: dextran sulfate, 10%; 2 × SSC at 74°C for 5 min and immediately applied to cells on slides that were hybridized overnight in a humidified chamber at 37°C. Slides were washed three times at 42°C in 2 × SSC, pH 7.0. Cell scoring was performed using a 100 × Plan Neofluor objective mounted on an Axioscope (Zeiss, Wetzlar, Germany). The control of normal bone marrow samples revealed positivity for trisomy 8 in 4% of the cells. The FISH analysis from patient No. 4 with AML M5b and trisomy 8 is shown in Figure 2 .
In vitro culturing and cytogenetic analysis
The FACS isolated cells were incubated at 37°C for 72 h in RPMI 1640 (GIBCO) supplemented with 20% FCS (HyClone, Logan, UT, USA), 100 U/ml recombinant human (rh) granulocyte colony-stimulating factor (Amgen, Thousand Oaks, CA, USA), 100 U/ml glycosylated rh granulocyte-macrophage colony-stimulating factor (Behringwerke, Marburg, Germany), 100 U/ml rh interleukin-3 (Behringwerke), 1 U/ml erythropoietin (Boehringer, Mannheim, Germany), and 50 ng/ml stem cell factor (Genzyme, Boston, MA, USA). Cells were incubated with 0.3 g/ml colcemide (GIBCO) for 12 h. Chromosome preparation and staining by a modified GAG-banding technique have been described previously. 34 The karyotypes were classified according to the International System of Chromosome Nomenclature (ISCN). 34 The cytogenetic analysis of a metaphase from the FACS sorted CD34
+ /CD38 − subpopulation from patient No. 1 with AML M2, add(2) is shown in Figure 3 .
Results
Bone marrow from seven informative patients (clonal abnormalities at diagnosis in the native bone marrow) with AML in morphological complete remission was analyzed ( Table 1) . The following FAB subtypes and leukemia-specific chromosomal abnormalities were observed: AML M2 (add(2)(q37)), M3 (t(15;17)+8), M4 (+4), M4 (+11,+13,+22), M4Eo (inv(16),+8), M5b (+8) and M2 (t(6;9),+8). The remission duration at analysis ranged between 3 and 33 months. Three patients are still in continuous complete remission (CCR). Patients 1 and 5 were analyzed twice during morphological complete remission. Patient 4 was analyzed during his first and second complete remission. Patient 6 underwent allogenic bone marrow transplantation after the analysis of his bone marrow which is shown here. The patients' ages ranged between 35 and 77 years. The following clonal chromosomal abnormalities were found in the unsorted bone marrow: add (2)(q37); t(15;17) +8; t(17;20); +4; +8; inv(16)+8; +11, +13, +21, +22 and t(6;9),+8). The cellular yield of sorted cells ranged from 12 to 4650 in the CD34 + /CD38 − and from 270 to 7200 in the CD34 + /CD38
+ subpopulation. Table 1 shows the patients' characteristics, immunophenotype, karyotype and cellular yield of the sorted bone marrow subpopulations.
Cytogenetic analysis of the unsorted bone marrow at diagnosis
Cytogenetic analysis of the unsorted bone marrow was performed from all patients at diagnosis. Three patients showed only 
Cytogenetic analysis of the unsorted bone marrow in morphological CR
Cytogenetic analysis of the unsorted bone marrow was performed from 5/7 patients during morphological complete remission (samples 1a, 1b, 2, 4b, 5a, 5b, 7). In one patient FISH analysis was performed during CR (patient 3). Only the leukemia-specific clonal chromosomal abnormality was found in 1/7 patients (patient 7), a mosaic of normal and aberrant metaphases was found in 3/7 patients (samples 1a, 1b, 4b, 5a) and only normal metaphases were detected in 2/7 patients (samples 2, 5b). Patient 3 also showed a mosaic of normal and abnormal interphases by FISH analysis. In two patients no metaphases were detected (samples 4a, 6). 
Cytogenetic analysis of the CD34
+ /38 − subpopulation in morphological CR
In eight samples we performed classical cytogenetics (sample 1a, 1b, 2, 4b, 5a, 5b, 6, 7). In the CD34
− population of 2/8 samples only the leukemia-specific clonal chromosomal abnormality could be detected (sample 1a and 7). One of the eight samples showed a mosaic of normal and abnormal metaphases (sample 1b). In 5/8 samples no metaphases were detected in the immature CD34 + /38 − population (sample 2, 4b, 5, 6, 7).
Figure 3
Metaphase from a CD34
+ /CD38 − cell from patient No. 1 showing additional material at chromosome 2 (add (2)).
Cytogenetic analysis of the CD34 + /38 + subpopulation in morphological CR
In the CD34 + /38 + population, 1/8 samples only showed the karyotypic abnormality known from diagnosis (sample 5a), 4/8 samples revealed a mosaic of normal and abnormal metaphases (sample 1a, 1b, 4b, 5b), 2/8 samples only showed normal metaphases (sample 2, 6), in one patient no metaphases could be found (sample 7).
FISH analysis of the CD34
+ /CD38 ± subpopulation in morphological CR In 2/7 patients FISH analysis was performed since the number of sorted cells of the CD34
− subpopulation was too small for the performance of classical cytogenetics. In the CD34 + /38 + subpopulation of both patients a mosaic of normal and aberrant cells was detected (patients 3 and 4). 
FACS analysis for minimal residual disease of the bone marrow
Immunophenotyping during morphological complete remission was performed in 6/7 patients. In 5/7 patients an abnormal immunophenotype was detected. Patients 1, 3 and 7 revealed an aberrant immunophenotype (patient 1, CD7/33/34; patient 3, CD7/13/33; and patient 7, CD2/56/33; Table 2 .
Clinical status
Taken together it was possible to detect leukemia-specific clonal chromosomal abnormalities in the immature, 
+ subpopulation of 4/7 patients, two of the patients already died from relapse (patients 1 and 4) whereas two of them are in continuous clinical remission (patients 3 and 5). In 2/7 patients it was even possible to detect abnormal metaphases in the most immature CD34
− stem cell compartment (patients 1 and 7). Both of them died from relapse. In one patient (patient 5) with inversion 16 the cytogenetic analysis of the unsorted sample only showed normal metaphases at the second time of analysis during CR, whereas the analysis of the sorted CD34
+ cells revealed a mosaic of normal and abnormal metaphases, this patient is still in complete clinical remission. The results are summarized in Table  1 and Figure 4 .
Discussion
Acute myeloid leukemia arise from the clonal expansion of a malignant transformed progenitor cell which can be charac- terized by the expression of CD34 and the absence of CD38 or other differentiation markers. [1] [2] [3] [4] [5] [6] [7] [8] Although 50-80% of all patients may achieve a complete remission the majority of these patients will ultimately relapse due to persistent leukemia. Several methods for detection and quantification of residual leukemic cells have been used. Clinical correlations between the number of residual leukemic cells and the probability of relapse have been made. [26] [27] [28] However, the the mechanism of survival of residual leukemic cells has not been clarified so far. The present analysis was performed to investigate whether these leukemic cells may survive intensive chemotherapy in the niche of the stem cell compartment. Our findings show that the analysis of highly purified early progenitor cells in patients with AML during morphological complete remission is possible even if the number of sorted cells is very small. In five of 10 samples, the leukemia-specific clonal chromosomal abnormality was detected in the immature CD34 + subpopulation using conventional cytogenetic analysis or FISH. The leukemic clone could even be detected in the most immature CD34
− subpopulation of one patient (patient 1 with add(2q)). Three of the five patients with minimal residual disease died due to relapse. Two patients are still in complete morphological remission. These findings indicate, that leukemic cells with an immature, stem cell-like immunophenotype can survive intensive chemotherapy in the niche of the stem cell compartment. The sensitivity of the analysis of sorted progenitor cells seems to be very high. Whenever the analysis of the sorted subpopulations was successful, clonal chromosomal abnormalities that were detected in the unsorted sample were also found in the sorted CD34 + cells. In one patient with inversion 16 the sensitivity was even higher than conventional cytogenetic analysis. In only seven of the 10 samples a comparison of the level of sensitivity between analysis of the sorted subpopulations and immunophenotyping can be drawn. Three of the seven samples revealed minimal residual disease due to the analysis of the progenitor cells as well as their immunophenotype. No minimal residual disease was observed by the immunophenotype in 4/7 samples. From these four samples, three revealed a persistence of the leukemia-associated clonal chromosomal abnormality in the immature CD34
+
/CD38
± stem cell compartment. This suggests that the analysis of FACS-sorted subpopulations can enhance the sensitivity of cytogenetics or FISH analysis and immunophenotyping for the detection of persistent leukemic cells. In conclusion, in hematological CR leukemia-associated clonal chromosomal abnormalities persist in subpopulations of CD34 + cells. Functional analysis is necessary to evaluate the leukemic potential of these residual leukemic cells and to perhaps further discriminate between normal and leukemic stem cells. Gene marking studies have already shown that persistent leukemic cells in autologous bone marrow transplants may contribute to relapse. 35, 36 The identification of leukemic stem cells may be of important relevance for future clinical trials which have to be directed against leukemic stem cells, not only against the bulk population of leukemia.
